EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma

Introduction: It has been well established that EGFR Thr790Met is one of the major resistance mechanisms to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs). Nevertheless, whether EGFR Thr790Leu (T790L), which shares the mutation site of Thr790 with EGFR Thr790Met, mediates resist...

Full description

Bibliographic Details
Main Authors: Chan Xiang, PhD, Wei Zhang, PhD, MD, Li-Wen Xiong, MD, Xu-Wei Cai, PhD, MD, Hao-Hua Teng, MD, Rui-Ying Zhao, MD, Zhan-Xian Shang, MD, Han Han-Zhang, PhD, Lu Zhang, PhD, Li Yan, MS, Zhi-Qiu Chen, MS, Yu-Chen Han, PhD, MD
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:JTO Clinical and Research Reports
Subjects:
EGFR T790L
Resistance mechanism
EGFR-TKI
Osimertinib
Lung adenocarcinoma
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000448

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321000448

Similar Items